RxDoctor Payments Data

Josephine Owens

Psychiatric/Mental Health · Corbin, KYNPI 1598337016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,279, more than ten times the $190 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,600in general payments, 2019–2025

Across 259 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Vanda Pharmaceuticals Inc.$811
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$707
  • Johnson & Johnson$630
  • AbbVie$570
  • Axsome Therapeutics, Inc.$531
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,55399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,600 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole30$43,534
TrintellixVortioxetine Hydrobromide19$19,035
Lurasidone Hcl11$3,056
Aripiprazole12$2,100
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,446
Fluvoxamine Maleate12$822
Bupropion XlBupropion Hcl20$250
Hydroxyzine Hcl14$245
Lamotrigine19$186
Escitalopram Oxalate17$183
Buspirone Hcl19$154
Lorazepam26$127
Trazodone Hcl25$119
Duloxetine Hcl19$107
Sertraline Hcl15$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,207$43,53430 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$74$19,03519 claims
Almatica Pharma LLCSertraline Hcl$73$6815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →